MedTrace Logo

Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care

NCT00794196 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2016-11-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the impact of pharmaceutical services among patients starting a treatment with antidepressants for a diagnosis of depression. The hypothesis of the study is that pharmacist intervention can improve compliance to antidepressants and patient wellbeing.

Conditions

Interventions

BEHAVIORAL

Pharmaceutical care program for antidepressant treatment

The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.

Sponsors & Collaborators

  • Carlos III Health Institute

    collaborator OTHER_GOV

  • Catalan Institute of Health

    collaborator OTHER_GOV

  • University of Barcelona

    collaborator OTHER

  • Fundació Sant Joan de Déu

    lead OTHER

Principal Investigators

  • Antoni Serrano, MD PhD · Foundation Sant Joan de Deu

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-11-30
Completion
2012-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00794196 on ClinicalTrials.gov